Based on the insights gained in our pioneering work in antisense and discovery and development of TLR-targeted compounds, Idera has introduced a novel approach to gene-silencing. This approach utilizes gene-silencing oligonucleotides (GSOs) comprised of synthetic DNA and RNA.
In preclinical studies, GSOs show length-dependent gene silencing activity, with 19 to 21-mers to be the most potent compared to other lengths. GSOs have shown activity when targeted to either messenger RNA or microRNA. In animal models, GSOs were more potent and showed longer duration of activity compared to antisense. For systemic application, no delivery enhancement technology has been required.(Publication)
Idera holds multiple patent applications for GSOs that are pending worldwide.